Pharmaceutical giant Eli Lilly And Co (NYSE:LLY) is set to launch its highly-anticipated obesity drug, Mounjaro (tirzepatide), in Britain this week, making the U.K. the fourth European country to introduce the famed medication.
The drug, also approved for diabetes treatment, is expected to address the pressing issue of obesity, with nearly one in three adults in Britain classified as obese, the highest rate in Europe.
Superdrug announced Wednesday that eligible private patients could obtain Mounjaro prescriptions through its Online Doctor service starting Thursday.
Related Content: Eli Lilly’s Weight Loss Drug Tirzepatide Is Expanding Market Share, Analyst Outlines What Lies Ahead.
Despite this, the retail chain prioritized National Health Service (NHS) patients, considering the anticipated high demand, drawing parallels with the popularity of Novo Nordisk A/S’s (NYSE:NVO) rival weight-loss drug, Wegovy, introduced in the UK last year.
Britain’s Simple Online Pharmacy, another key player in the pharmacy landscape, reported the commencement of Mounjaro prescriptions on Tuesday.
Citing a spokesperson from Simple, Reuters highlighted the broad availability of Mounjaro across all pharmacies in the UK, which is accessible to both NHS and private patients.
Simple has a waitlist of over 80,000 patients seeking a weight-loss treatment, the spokesperson added.
In January, The Medicines and Healthcare Products Regulatory Agency (MHRA) approved a four-dose version of the diabetes and weight management medicine Mounjaro.
Britain became the first major market to receive Mounjaro in the new pen, known as Kwikpen, which is capable of delivering four weekly subcutaneous shots.
While Germany, Switzerland, and Poland have already witnessed the launch of Mounjaro, the U.K. market eagerly anticipates this development.
Unlike these countries, where the drug is packaged in vials, the British market will benefit from the convenience of the pre-filled injection pen.
Superdrug and Simple have revealed the pricing details for Mounjaro in the UK. A 4-week course at 2.5 milligrams and 5 mg starter doses will be available for private patients at £215 ($270) and £189, respectively.
LLY Stock Prediction For 2030
Predicting the future in stock prices over long periods of time is challenging. Wall…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
